Format

Send to

Choose Destination
J Pharm Sci. 2017 May;106(5):1317-1321. doi: 10.1016/j.xphs.2017.01.016. Epub 2017 Jan 19.

A Study of Fasoracetam's Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical.

Author information

1
Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
2
Namur Institute for Life Sciences (Narilis), University of Namur, Namur, Belgium.
3
Institute of Condensed Matter and Nanosciences, Université Catholique de Louvain, Louvain-la-Neuve, Belgium. Electronic address: Tom.Leyssens@uclouvain.be.

Abstract

Different solid state forms of the research chemical fasoracetam, which counters the effects of Alzheimer's disease, have been subjected to a thermal and structural analysis. Single crystals were obtained from solution evaporation and from the melt. Single-crystal X-ray analyses of the crystals show the existence of 2 hydrated and 1 non-hydrated crystalline form of fasoracetam. Under ambient conditions, the hydrate form I is found to be the most stable form, showing a melting point of 57C. This low melting point, combined with possible water losses could cause problems when formulating the hydrated form and impact the storage conditions of the compound.

KEYWORDS:

Alzheimer’s disease; calorimetry (DSC); crystal structure; hydrate; polymorphism; solvent evaporation; thermogravimetric analysis

PMID:
28109793
DOI:
10.1016/j.xphs.2017.01.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center